Danielle C. Pappas
Research Subjects
Danielle C. Pappas has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Henry C. Nguyen
Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
56 shared publications - Kelly D. Moynihan
Asher Biotherapeutics, Inc., South San Francisco, California. 1
56 shared publications - Nathan D. Mathewson
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
56 shared publications - Hussein Sultan
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
55 shared publications - Irene Ni
Asher Biotherapeutics, Inc., South San Francisco, California. 1
55 shared publications - Ivana M. Djuretic
Asher Biotherapeutics, Inc., South San Francisco, California. 1
55 shared publications
Latest Publications
- 30 July 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1424.e1-1424.e19
Cis-targeted IL-2 Mutein to Augment the Antitumor Activity of Engineered T Cells
- 30 July 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1424.e1-1424.e19
Cis-targeted IL-2 Mutein to Augment the Antitumor Activity of Engineered T Cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S3, Single-cell RNA sequencing reagents used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S3, Single-cell RNA sequencing reagents used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S3: Biodistribution of cytokine fusion molecules in tumor-bearing mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S3: Biodistribution of cytokine fusion molecules in tumor-bearing mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S1, Molecules used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S1, Molecules used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S1: CD8+ T cells drive anti-tumor activity but NK cells are responsible for toxicity with not-α-IL2 therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S1: CD8+ T cells drive anti-tumor activity but NK cells are responsible for toxicity with not-α-IL2 therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S8: Differential expression by treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S8: Differential expression by treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S7: Sub-clustering of naïve-like/recently activated cluster and characterization of clonal expansion and antigen.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S7: Sub-clustering of naïve-like/recently activated cluster and characterization of clonal expansion and antigen.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S5: Anti-tumor activity of CD8-mIL2 in combination with anti-PD-1 in B16F10, 1956, MCA-205, and KP.mLama4 tumor models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S5: Anti-tumor activity of CD8-mIL2 in combination with anti-PD-1 in B16F10, 1956, MCA-205, and KP.mLama4 tumor models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S9: scRNAseq analysis of MC38 tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S9: scRNAseq analysis of MC38 tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S6: Characterization of antigen-specific CD8+ T cells in MC38 tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S6: Characterization of antigen-specific CD8+ T cells in MC38 tumors.